Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ewing sarcoma.
Grünewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, Sorensen PH, Delattre O, Dirksen U. Grünewald TGP, et al. Among authors: dirksen u. Nat Rev Dis Primers. 2018 Jul 5;4(1):5. doi: 10.1038/s41572-018-0003-x. Nat Rev Dis Primers. 2018. PMID: 29977059 Review.
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslböck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jürgens H, Kovar H. Le Deley MC, et al. Among authors: dirksen u. J Clin Oncol. 2010 Apr 20;28(12):1982-8. doi: 10.1200/JCO.2009.23.3585. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308673
Approaching Ewing sarcoma.
Dirksen U, Jürgens H. Dirksen U, et al. Future Oncol. 2010 Jul;6(7):1155-62. doi: 10.2217/fon.10.76. Future Oncol. 2010. PMID: 20624127 Review.
Risk of recurrence and survival after relapse in patients with Ewing sarcoma.
Stahl M, Ranft A, Paulussen M, Bölling T, Vieth V, Bielack S, Görtitz I, Braun-Munzinger G, Hardes J, Jürgens H, Dirksen U. Stahl M, et al. Among authors: dirksen u. Pediatr Blood Cancer. 2011 Oct;57(4):549-53. doi: 10.1002/pbc.23040. Epub 2011 Mar 25. Pediatr Blood Cancer. 2011. PMID: 21442722
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Mackintosh C, Ordóñez JL, García-Domínguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, Scotlandi K, Alberghini M, Sciot R, Sinnaeve F, Hogendoorn PC, Picci P, Knuutila S, Dirksen U, Debiec-Rychter M, Schaefer KL, de Álava E. Mackintosh C, et al. Among authors: dirksen u. Oncogene. 2012 Mar 8;31(10):1287-98. doi: 10.1038/onc.2011.317. Epub 2011 Aug 8. Oncogene. 2012. PMID: 21822310
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.
Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A. Juergens H, et al. Among authors: dirksen u. J Clin Oncol. 2011 Dec 1;29(34):4534-40. doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24. J Clin Oncol. 2011. PMID: 22025154 Free PMC article. Clinical Trial.
Ewing sarcoma: clinical state-of-the-art.
Potratz J, Dirksen U, Jürgens H, Craft A. Potratz J, et al. Among authors: dirksen u. Pediatr Hematol Oncol. 2012 Feb;29(1):1-11. doi: 10.3109/08880018.2011.622034. Pediatr Hematol Oncol. 2012. PMID: 22295994 Review.
222 results